Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux
On June 30, 2021, ONXEO reported liquidity contract details with Kepler Cheuvreux. The liquidity account held 448,434 shares and €33,899.60. During the semester, there were 255 buy-side executions for 269,935 shares worth €99,624.74, and 222 sell-side executions for 251,351 shares worth €96,727.03. In the previous half-year statement on December 31, 2021, the account had 429,850 shares and €36,891.92. The report complies with AMF Decision N°2021-01, renewing liquidity contracts as an accepted market practice.
- Increase in liquidity account shares from previous report: 448,434 shares vs. 429,850 shares.
- Consistent trading activity with 255 buy executions indicating investor interest.
- Reduction in cash available in liquidity account from €36,891.92 to €33,899.60.
- Higher sell-side executions (222) compared to buy-side (255), indicating potential selling pressure.
Under the liquidity contract entered into between
- 448,434 shares
-
- Number of executions on buy side on semester: 255
- Number of executions on sell side on semester: 222
- Traded volume on buy side on semester: 269,935 shares for
- Traded volume on sell side on semester: 251,351 shares for
As a reminder:
-
the following resources appeared on the last half year statement on
31 December 2021 on the liquidity account:
- 429,850 shares
-
- Number of executions on buy side on semester: 256
- Number of executions on sell side on semester: 155
- Traded volume on buy side on semester: 357,510 shares for
- Traded volume on sell side on semester: 221,580 shares for
• the following resources appeared on the liquidity account when the activity started:
- 87,612 shares
-
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of
About
platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.
AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in
OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
For further information, please visit www.onxeo.com.
Forward looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning
APPENDIX
|
Buy Side |
Sell Side |
|||||
|
Number of
|
Number of
|
Traded volume
|
Number of
|
Number of
|
Traded volume
|
|
Total |
255 |
269,935 |
99,624.74 |
222 |
251,351 |
96,727.03 |
|
|
- |
- |
- |
2 |
10,000 |
4,400.00 |
|
|
3 |
5,000 |
2,200.00 |
1 |
5,000 |
2,250.00 |
|
|
2 |
5,000 |
2,150.00 |
- |
- |
- |
|
|
2 |
5,000 |
2,100.00 |
- |
- |
- |
|
|
- |
- |
- |
14 |
7,267 |
3,124.81 |
|
|
2 |
4,193 |
1,761.06 |
- |
- |
- |
|
|
6 |
5,807 |
2,497.01 |
3 |
12,733 |
5,602.52 |
|
1 | 4,645 | 1,997.35 | - | - | - | ||
|
3 |
7,786 |
3,347.98 |
1 |
5,000 |
2,200.00 |
|
|
1 |
2,569 |
1,078.98 |
- |
- |
- |
|
|
1 |
5,000 |
2,050.00 |
- |
- |
- |
|
|
3 |
5,000 |
2,000.00 |
1 |
1 |
0.42 |
|
|
- |
- |
- |
2 |
5,000 |
2,050.00 |
|
|
2 |
1,443 |
577.20 |
- |
- |
- |
|
|
1 |
1 |
0.40 |
2 |
2,894 |
1,215.48 |
|
1 | 3,556 | 1,422.40 | - | - | - | ||
|
- |
- |
- |
1 |
2,133 |
874.53 |
|
|
3 |
625 |
243.75 |
- |
- |
- |
|
|
6 |
4,376 |
1,706.64 |
1 |
1 |
0.40 |
|
|
1 |
1 |
0.40 |
1 |
1 |
0.40 |
|
|
1 |
1 |
0.40 |
1 |
1 |
0.40 |
|
|
4 |
10,000 |
3,800.00 |
1 |
1 |
0.38 |
|
4 | 5,000 | 1,800.00 | 5 | 1,529 | 565.73 | ||
|
- |
- |
- |
10 |
3,471 |
1,284.27 |
|
|
13 |
15,235 |
5,332.25 |
- |
- |
- |
|
|
2 |
4,765 |
1,572.45 |
9 |
6,071 |
2,064.14 |
|
|
- |
- |
- |
7 |
8,929 |
3,125.15 |
|
3 | 2,410 | 819.40 | 8 | 25,000 | 9,250.00 | ||
|
4 |
4,362 |
1,570.32 |
2 |
301 |
114.38 |
|
|
- |
- |
- |
1 |
1 |
0.38 |
|
|
10 |
18,475 |
6,281.50 |
- |
- |
- |
|
13 | 15,000 | 4,800.00 | - | - | - | ||
- | - | - | 2 | 5,000 | 1,650.00 | ||
- | - | - | 7 | 18,860 | 6,789.60 | ||
|
1 |
5,000 |
1,700.00 |
- |
- |
- |
|
|
1 |
1 |
0.35 |
2 |
2,001 |
720.36 |
|
|
1 |
1 |
0.35 |
1 |
2,000 |
740.00 |
|
|
2 |
2,001 |
720.36 |
1 |
1 |
0.36 |
|
4 | 2,122 | 742.70 | 2 | 2,000 | 740.00 | ||
|
- |
- |
- |
4 |
2,000 |
740.00 |
|
|
3 |
2,001 |
720.36 |
1 |
1 |
0.37 |
|
|
7 |
2,001 |
720.36 |
5 |
2,001 |
720.36 |
|
|
2 |
555 |
194.25 |
3 |
2,000 |
720.00 |
|
4 | 2,000 | 720.00 | 1 | 100 | 37.00 | ||
|
2 |
180 |
63.00 |
- |
- |
- |
|
|
1 |
1,265 |
442.75 |
5 |
2,001 |
740.37 |
|
|
- |
- |
- |
20 |
29,899 |
11,959.60 |
|
|
2 |
930 |
372.00 |
2 |
4,000 |
1,720.00 |
|
|
- |
- |
- |
4 |
4,000 |
1,720.00 |
|
|
3 |
4,000 |
1,720.00 |
6 |
8,000 |
3,440.00 |
|
|
3 |
4,000 |
1,640.00 |
4 |
3,842 |
1,652.06 |
|
|
6 |
8,000 |
3,360.00 |
- |
- |
- |
|
|
- |
- |
- |
1 |
2,000 |
840.00 |
|
|
1 |
1 |
0.41 |
1 |
1 |
0.41 |
|
|
4 |
6,615 |
2,579.85 |
3 |
2,000 |
800.00 |
|
|
4 |
6,000 |
2,280.00 |
- |
- |
- |
|
|
1 |
2,000 |
760.00 |
1 |
2,000 |
780.00 |
|
|
3 |
2,000 |
760.00 |
3 |
6,000 |
2,340.00 |
|
|
1 |
1 |
0.39 |
4 |
2,838 |
1,135.20 |
|
|
3 |
2,000 |
780.00 |
- |
- |
- |
|
|
2 |
127 |
49.53 |
2 |
1,164 |
465.60 |
|
|
3 |
3,875 |
1,511.25 |
1 |
1 |
0.39 |
|
|
5 |
2,001 |
760.38 |
1 |
1 |
0.38 |
|
|
2 |
1,881 |
695.97 |
- |
- |
- |
|
|
3 |
2,120 |
784.40 |
2 |
401 |
152.38 |
|
|
- |
- |
- |
2 |
445 |
169.10 |
|
|
2 |
2,001 |
720.36 |
1 |
1 |
0.38 |
|
|
7 |
5,999 |
2,099.65 |
- |
- |
- |
|
|
2 |
780 |
273.00 |
4 |
4,000 |
1,440.00 |
|
|
3 |
3,220 |
1,127.00 |
- |
- |
- |
|
|
1 |
800 |
280.00 |
2 |
4,000 |
1,440.00 |
|
|
- |
- |
- |
5 |
4,000 |
1,440.00 |
|
|
3 |
3,200 |
1,120.00 |
- |
- |
- |
|
|
2 |
4,000 |
1,360.00 |
- |
- |
- |
|
|
- |
- |
- |
2 |
2,000 |
700.00 |
|
|
3 |
4,000 |
1,360.00 |
- |
- |
- |
|
|
- |
- |
- |
1 |
2,000 |
700.00 |
|
|
1 |
1 |
0.34 |
2 |
2,001 |
700.35 |
|
|
6 |
2,000 |
680.00 |
1 |
1,000 |
350.00 |
|
|
1 |
1 |
0.34 |
1 |
1 |
0.34 |
|
|
1 |
35 |
11.90 |
1 |
2,000 |
700.00 |
|
|
1 |
1 |
0.35 |
1 |
1 |
0.35 |
|
|
6 |
3,965 |
1,387.75 |
1 |
1 |
0.36 |
|
|
2 |
81 |
28.35 |
5 |
2,000 |
720.00 |
|
|
1 |
523 |
183.05 |
- |
- |
- |
|
|
1 |
1 |
0.35 |
- |
- |
- |
|
|
1 |
1 |
0.36 |
5 |
2,029 |
730.44 |
|
|
2 |
3,396 |
1,188.60 |
- |
- |
- |
|
|
1 |
2,000 |
680.00 |
- |
- |
- |
|
|
- |
- |
- |
1 |
1 |
0.35 |
|
|
3 |
2,000 |
680.00 |
1 |
1,999 |
699.65 |
|
|
6 |
4,127 |
1,444.45 |
- |
- |
- |
|
|
8 |
11,873 |
3,918.09 |
2 |
3,767 |
1,243.11 |
|
|
3 |
3,199 |
1,023.68 |
2 |
3,500 |
1,155.00 |
|
|
1 |
801 |
248.31 |
4 |
1,157 |
381.81 |
|
|
1 |
120 |
38.40 |
4 |
4,000 |
1,320.00 |
|
|
2 |
3,880 |
1,241.60 |
- |
- |
- |
|
|
1 |
1 |
0.33 |
1 |
1 |
0.33 |
|
|
- |
- |
- |
4 |
6,000 |
2,040.00 |
|
|
3 |
2,251 |
742.83 |
4 |
3,272 |
1,112.48 |
|
|
3 |
1,284 |
436.56 |
3 |
2,729 |
955.15 |
|
|
6 |
2,716 |
923.44 |
- |
- |
- |
|
|
3 |
753 |
248.49 |
- |
- |
- |
|
|
2 |
2,997 |
989.01 |
- |
- |
- |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005354/en/
Investor Relations
investors@onxeo.com
+33 1 45 58 76 00
Media Relations
Arthur Rouillé
NewCap
onxeo@newcap.eu
+33 1 44 71 94 98
Investor Relations / Strategic Communication
Dušan Orešanský /
NewCap
onxeo@newcap.eu
+33 1 44 71 94 92
Certified Adviser for Nasdaq First North
Kapital Partner
www.kapitalpartner.dk
info@kapitalpartner.dk
+45 89 88 78 46
Source:
FAQ
What are the key figures from ONXEO's liquidity report on June 30, 2021?
How did ONXEO's liquidity account change from December 31, 2021, to June 30, 2021?
What is the significance of the liquidity contract for ONXEO?